ABT - Abbott Labs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABT - Abbott Labs

ABT 124.70

+0.2%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Frostman who wrote (284)	6/30/2000 10:16:01 AM
From: Skywatcher	Read Replies (2) of 328

TAP withdraws impotence drug application LAKE FOREST, Ill., June 30 (Reuters) - TAP Pharmaceutical Products Inc. said on Friday it was withdrawing the new drug application for its impotence drug Uprima and would resubmit it with new data at a later date. TAP, a joint venture between Illinois-based Abbott Laboratories Inc. (NYSE:ABT - news) and Japan's Takeda Chemical Industries Ltd. , said it was withdrawing the application because it has additional data and continuing studies that could further establish the drug's safety and efficacy. TAP licensed apomorphine HCl tablets, which it calls Uprima, from Pentech Pharmaceuticals Inc. of Deerfield, Ill. I think this could be a positive if indeed the new information gives the drug application a lot more strength since it has been somewhat controversial up to this point. chris

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next